A patient is anxious about what his therapist truly thinks about him. Does the patient have a right to review the therapist’s ...
New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA ...
New BPEI preclinical data address treatment protocol, corneal biochemical environment, fungal resistance mechanism, MRSA biofilm inhibition, and ...
The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...
Conference Call and Webcast Today at 8:30 a.m. ETPositive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) ...
Musunuri said Ocugen “remain[s] on track to file 3 BLAs over next 3 years by 2028,” and described “the first half of 2027 as a catalyst-rich window” with “Phase III top line data for OCU400, top line ...
Over the past few years, specialty care has seen a surge in artificial intelligence (AI) tools designed to reduce ...
When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...
Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...
Empirical research on AI and mental health is burgeoning. Some studies are using waitlist controls. Here's what you need to ...
Initial CX-801 clinical data in advanced melanoma, both as monotherapy and in combination with KEYTRUDA, are expected by the end of 2026, with observed tolerability at doses surpassing the approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results